Efrat Makov Buys Shares of CRNT
Efrat Makov acquired 5,000 shares of CRNT, highlighting insider interest.
Key Points
- Efrat Makov bought 5,000 shares of CRNT at $1.99 each, totaling $9,950, on June 12, 2026.
- CRNT shares trade near $2.99. The stock has seen varied institutional interest, with some funds increasing and others reducing their holdings.
- Analysts such as Needham and Lake Street maintain a positive outlook on CRNT, reiterating buy ratings with targets up to $3.5.
Efrat Makov recently purchased 5,000 shares of CRNT at a price of $1.99 each, for a total transaction value of $9,950. This insider activity on June 12, 2026, reflects a personal investment in the company.
Other Institutional Activity in CRNT
In recent institutional moves, First Wilshire Securities Management Inc increased its holdings by 740,358 shares, bringing its total to about 4.85 million shares valued at approximately $10.48 million. Meanwhile, CSM Advisors, LLC slightly reduced its position by 11,650 shares, now holding roughly 2.27 million shares worth $4.91 million. Private Advisor Group, LLC also trimmed its stake by 10,000 shares to 1.41 million shares, valued at $3.05 million. WealthTrust Axiom LLC added 43,836 shares, ending with about 944,135 shares valued at $2.04 million. KLCM Advisors, Inc. made no changes, maintaining its stake at 795,500 shares valued at $1.72 million.
CRNT Stock Snapshot
CRNT shares are trading near $2.99. The stock has seen a range of institutional interest, with some funds increasing and others reducing their holdings. CRNT's market performance and insider activities suggest ongoing interest in the company's future prospects.
Insider Buying and Selling at CRNT
Alongside Efrat Makov's purchase, Doron Ovadia Arazi, CRNT's CEO, also bought shares on June 11, 2026. Arazi acquired 133,333 shares without a specified price, indicating a substantial increase in personal investment. Rami Hadar bought 29,500 shares on May 23, 2026, further demonstrating insider confidence.
Analysts Set New Price Targets
On May 20, 2026, Needham reiterated its buy rating for CRNT with a price target of $3.00. Earlier, on March 31, 2026, Lake Street initiated coverage with a buy rating and a target of $3.50. These ratings reflect a positive outlook from analysts, suggesting potential growth.
Bottom Line
Efrat Makov's recent purchase of CRNT shares, along with other insider activities, reflects a notable level of insider confidence. Institutional movements show mixed sentiments, with some funds increasing and others reducing their stakes. Analysts maintain a positive outlook on CRNT, underscoring potential growth opportunities. As always, these insights are based on reported data and do not necessarily reflect the current holdings or future actions.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.